Patents by Inventor Anatoly Kachurin
Anatoly Kachurin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9625444Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: GrantFiled: March 20, 2014Date of Patent: April 18, 2017Assignees: SANOFI PASTEUR VAXDESIGN CORPORATION, THE SCRIPPS RESEARCH INSTITUTE, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITYInventors: William L Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Hacohen, Bruce Torbett
-
Patent number: 9566250Abstract: The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.Type: GrantFiled: January 13, 2014Date of Patent: February 14, 2017Assignee: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Ayesha Mahmood, Anatoly Kachurin, William Warren, Russell Higbee
-
Patent number: 9541545Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: GrantFiled: June 3, 2014Date of Patent: January 10, 2017Assignee: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia
-
Publication number: 20150111766Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: ApplicationFiled: June 3, 2014Publication date: April 23, 2015Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Anatoly KACHURIN, Olga KACHURINA, Vaughan WITTMAN, Tenekua TAPIA
-
Patent number: 8962256Abstract: Hemagglutination (HA) and hemagglutination inhibition (HAI) functional assays remain important instruments of analysis of virus-cell interaction and protecting efficacy of virus-specific antibodies and sera. However, they demonstrate limited sensitivity towards many viruses, and require significant volumes of viruses, erythrocytes, sera, and antibodies. The present invention comprises new and significantly more sensitive versions of the HA and HAI assays based on observing agglutination on activated surfaces of specifically opsonized plates and ELISA plates rather than in solution. A version of the new assay that uses ELISA plates additionally allows characterizing the affinity of functional antibodies in the tested sera and fluids, which is not possible in the classical HAI assay. The methods of the present invention can also be used to improve the sensitivity of agglutination methods based on latex beads and to develop agglutination methods using target cells other than erythrocytes.Type: GrantFiled: October 20, 2010Date of Patent: February 24, 2015Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Anatoly Kachurin, Vaughan Wittman, Mike N. Nguyen, Olga Kachurina, Tenekua Tapia, Vipra Dhir, Alexander Karol
-
Publication number: 20140273209Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: ApplicationFiled: March 20, 2014Publication date: September 18, 2014Applicants: SANOFI PASTEUR VAXDESIGN CORPORATION, THE SCRIPPS RESEARCH INSTITUTE, MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: William L WARREN, Heather FAHLENKAMP, Russell HIGBEE, Anatoly KACHURIN, Conan LI, Mike NGUYEN, Robert PARKHILL, Guzman SANCHEZ-SCHMITZ, Darrell J. IRVINE, Gwendalyn J. RANDOLPH, Nir HACOHEN, Bruce TORBETT
-
Patent number: 8778347Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: GrantFiled: November 11, 2009Date of Patent: July 15, 2014Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia
-
Publication number: 20140147482Abstract: The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.Type: ApplicationFiled: January 13, 2014Publication date: May 29, 2014Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Ayesha MAHMOOD, Anatoly KACHURIN, William WARREN, Russell HIGBEE
-
Patent number: 8722402Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: GrantFiled: September 10, 2012Date of Patent: May 13, 2014Assignees: Sanofi Pasteur Vaxdesign Corporation, Mount Sinai School of Medicine, The Whitehead Institute, Massachusetts Institute of Technology, The Scripps Research InstituteInventors: William L Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Harcohen, Bruce Torbett
-
Patent number: 8647837Abstract: The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.Type: GrantFiled: July 16, 2008Date of Patent: February 11, 2014Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Ayesha Mahmood, Anatoly Kachurin, William Warren, Russell Higbee
-
Publication number: 20130078656Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: ApplicationFiled: September 10, 2012Publication date: March 28, 2013Applicants: SANOFI PASTEUR VAXDESIGN CORPORATION, THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE SCRIPPS RESEARCH INSTITUTEInventors: William L. WARREN, Heather FAHLENKAMP, Russell HIGBEE, Anatoly KACHURIN, Conan LI, Mike NGUYEN, Robert PARKHILL, Guzman SANCHEZ-SCHMITZ, Darrell J. IRVINE, Gwendalyn J. RANDOLPH, Nir HACOHEN, Bruce TORBETT
-
Patent number: 8298823Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.Type: GrantFiled: March 24, 2010Date of Patent: October 30, 2012Assignee: Sanofi Pasteur Vaxdesign CorporationInventors: William L. Warren, Robert Parkhill, Michael N. Nguyen, Guzman Sanchez-Schmitz, Heather Fahlenkamp, Russell Higbee, Donald Drake, III, Anatoly Kachurin, David Moe
-
Patent number: 8288159Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: GrantFiled: March 17, 2010Date of Patent: October 16, 2012Assignee: Sanofi Pasteur Vaxdesign Corp. et al.Inventors: William L Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Harcohen, Bruce Torbett
-
Publication number: 20110171689Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: ApplicationFiled: March 17, 2010Publication date: July 14, 2011Applicant: VAXDESIGN CORPORATIONInventors: William L. Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Hacohen, Bruce Torbett
-
Publication number: 20110097705Abstract: Hemagglutination (HA) and hemagglutination inhibition (HAI) functional assays remain important instruments of analysis of virus-cell interaction and protecting efficacy of virus-specific antibodies and sera. However, they demonstrate limited sensitivity towards many viruses, and require significant volumes of viruses, erythrocytes, sera, and antibodies. The present invention comprises new and significantly more sensitive versions of the HA and HAI assays based on observing agglutination on activated surfaces of specifically opsonized plates and ELISA plates rather than in solution. A version of the new assay that uses ELISA plates additionally allows characterizing the affinity of functional antibodies in the tested sera and fluids, which is not possible in the classical HAI assay. The methods of the present invention can also be used to improve the sensitivity of agglutination methods based on latex beads and to develop agglutination methods using target cells other than erythrocytes.Type: ApplicationFiled: October 20, 2010Publication date: April 28, 2011Applicant: VAXDESIGN CORP.Inventors: Anatoly Kachurin, Vaughan Wittman, Mike N. Nguyen, Olga Kachurina, Tenekua Tapia, Vipra Dhir, Alexander Karol
-
Patent number: 7855074Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: GrantFiled: April 28, 2005Date of Patent: December 21, 2010Assignee: VaxDesign Corp.Inventors: William L. Warren, Heather Fahlenkamp, Russell Higbee, Anatoly Kachurin, Conan Li, Mike Nguyen, Robert Parkhill, Guzman Sanchez-Schmitz, Darrell J. Irvine, Gwendalyn J. Randolph, Nir Hacohen, Bruce Torbett
-
Patent number: 7785883Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.Type: GrantFiled: March 15, 2006Date of Patent: August 31, 2010Assignee: Vax Design Corp.Inventors: William L. Warren, Robert Parkhill, Michael N. Nguyen, Guzman Sanchez-Schmitz, Heather Fahlenkamp, Russell Higbee, Donald Drake, III, Anatoly Kachurin, David Moe
-
Publication number: 20100178676Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.Type: ApplicationFiled: March 24, 2010Publication date: July 15, 2010Applicant: VAXDESIGN CORP.Inventors: William L. WARREN, Robert PARKHILL, Michael N. NGUYEN, Guzman SANCHEZ-SCHMITZ, Heather FAHLENKAMP, Russell HIGBEE, Donald DRAKE, III, Anatoly KACHURIN, David MOE
-
Publication number: 20100120020Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: ApplicationFiled: November 11, 2009Publication date: May 13, 2010Applicant: VaxDesign Corp.Inventors: Anatoly KACHURIN, Olga KACHURINA, Vaughan WITTMAN, Tenekua TAPIA
-
Publication number: 20090325148Abstract: Hemagglutination assays and hemagglutination inhibition assays were introduced in medical and virology practice more than 60 years ago. Since then, these assays have become important tools for measuring concentrations and strengths of viral cultures, the efficacy of the anti-viral immunization, and for studying the neutralizing capacity of virus-specific antibodies. The present invention comprises an improved hemagglutination inhibition assay (HAI), with at least about a 10-fold increase in sensitivity versus the traditional the HAI, to provide more accurate measurements of components in, for example, fluids from the in vitro MIMICĀ® system when assessing the effects of anti-viral vaccines (e.g., for seasonal influenza).Type: ApplicationFiled: June 30, 2009Publication date: December 31, 2009Inventors: Anatoly KACHURIN, Vaughan WITTMAN, Olga KACHURINA, Tenekua TAPIA